Glaukos (NYSE:GKOS) announced today that it entered into exchange agreements to repurchase approximately $230 million. The company entered into separate, privately negotiated exchange agreements with certain holders of 2.75% convertible senior notes due 2027. Pursuant to these agreements, the company agreed to repurchase $230 million of existing convertible notes for aggregate consideration of shares of […]
Glaukos
FDA approves Glaukos iDose TR glaucoma-treating drug delivery implant
Glaukos (NYSE:GKOS) announced today that the FDA approved a New Drug Application (NDA) for its iDose TR implant. The approval allows for one administration per eye of iDose TR (travoprost intracameral implant) 75 mcg. The indication for the prostaglandin analog covers the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle […]
Glaukos beats Wall Street sales expectations in Q2
Glaukos (NYSE:GKOS) shares posted second-quarter financial results that came in well ahead of the consensus revenue forecast. Shares of GKOS remained relatively unmoved at $74.72 apiece after the market closed today. The Aliso Viejo–based ophthalmic medical technology company posted losses of $32.8 million. That amounts to 68¢ per share on sales of $80.4 million for […]
Glaukos agrees to market Radius XR’s wearable diagnostics in the U.S.
Glaukos (NYSE:GKOS) announced today that it entered into a collaboration and marketing agreement with Radius XR. Aliso Viejo, California-based Glaukos becomes the exclusive sales agent for the Radius XR wearable patient engagement and diagnostic system. The agreement gives the company the rights to market, promote and solicit orders for the platform in the U.S. Under […]
Glaukos stock rises on 9% Q1 revenue growth
Glaukos (NYSE:GKOS) shares ticked up this morning on first-quarter results that came in mixed compared to the consensus forecast. Shares of GKOS rose 9% at $50.66 apiece as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — dipped 0.03%. The (LOCATION)-based company posted losses […]
Celanese to provide drug delivery platform for Glaukos glaucoma treatment
Celanese (NYSE:CE) announced today that it entered into an agreement with Glaukos (NYSE:GKOS) over drug delivery for glaucoma treatments. Dallas-based Celanese agreed to supply its VitalDose drug delivery platform for use as a component in Gluakos’ iDose TR. The iDose TR serves as a micro-invasive intraocular implant for lowering intraocular pressure. It treats patients with […]
Glaukos submits FDA New Drug Application for iDose TR drug-eluting implant
Glaukos (NYSE:GKOS) announced today that it submitted a New Drug Application (NDA) to the FDA for its iDose TR implant. Aliso Viejo, California-based Glaukos designed iDose TR as a micro-invasive intraocular implant. It continuously delivers therapeutic levels of a proprietary formulation of travoprost from within the eye over extended periods of time. Once all travoprost […]
Glaukos beats The Street in Q4
Glaukos (NYSE:GKOS) shares took a hit today despite fourth-quarter results that topped the consensus forecast. Shares of GKOS dipped 7% at $46.90 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 8.1%. The Aliso Viejo, California-based ophthalmic implant maker posted losses of […]
Glaukos beats The Street in Q3
Glaukos (NYSE:GKOS) shares hardly shifted on third-quarter results that came in ahead of the consensus forecast. The Aliso Viejo, California-based ophthalmic implant maker posted losses of $27.6 million in the quarter. That amounts to 58¢ per share on sales of $71.3 million for the three months ended Sept. 30, 2022. Get the full story at […]
5 top ophthalmic device innovations you need to know
Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye. Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old […]
Phase 3 trial data support Glaukos iDose eye drop alternative
Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]
